At a glance
ClinicalIndex Comparison RecordN/ACompleted· 52 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Registry for Patients With WT1 Mutation Associated Diseases
In Brief
An observational study for Denys-Drash Syndrome and 3 related conditions. Completed, enrolled 52 participants across 1 site.
Detailed Summary
The Wilms' tumor suppressor gene 1 (WT1) encodes for a transcription factor which plays an important role during urogenital development. Patients carrying a WT1 germline mutation show symptoms like proteinuria, Wilms tumors, genital malformations and kidney failure. Milder variants are possible and classification is not always possible. In this registry we are collecting detailed clinical data of affected individuals to establish genotype-phenotype correlations with the greater goal to optimize patient care.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedDec 2010
Primary CompletionNov 2013
Study CompletionJun 2014
TodayJul 2026
First PostedDec 3, 2010
Enrollment StartOct 1, 2010
Primary CompletionNov 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.6 years ago